The National Forum’s Value & Access Collaboration provided consensus feedback on the Institute for Clinical and Economic Review (ICER)’s draft evidence report of the assessment for comparative clinical effectiveness and value of mavacamten for hypertrophic cardiomyopathy.
Signers included:
National Forum for Heart Disease & Stroke Prevention (convener)
American Association of Heart Failure Nurses
American College of Cardiology
American Heart Association
American Pharmacists Association Foundation
American Society for Preventive Cardiology
Association of Black Cardiologists
Association of State and Territorial Health Officials
BallengeRx Consulting
Global Healthy Living Foundation
Hypertrophic Cardiomyopathy Association
Independent Health
Institute for Patient Access
Mended Hearts
National Alliance of Healthcare Purchaser Coalitions
Partnership to Advance Cardiovascular Health
Partnership to Improve Patient Care
Preventive Cardiovascular Nurses Association
University of Michigan Center for Value-Based Insurance Design
WomenHeart
